News articles about Assembly Biosciences (NASDAQ:ASMB) have been trending somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Assembly Biosciences earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 43.7661397508471 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Assembly Biosciences (NASDAQ ASMB) opened at $45.77 on Wednesday. The company has a market capitalization of $909.91, a P/E ratio of -15.41 and a beta of 0.91. Assembly Biosciences has a 12-month low of $14.52 and a 12-month high of $52.37.
Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $0.17. analysts forecast that Assembly Biosciences will post -3.15 EPS for the current fiscal year.
Several brokerages recently weighed in on ASMB. Zacks Investment Research cut Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Monday. B. Riley began coverage on Assembly Biosciences in a research report on Friday, January 5th. They set a “neutral” rating and a $35.00 price target for the company. BidaskClub cut Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. ValuEngine cut Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Finally, Jefferies Group assumed coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $39.25.
In other news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $49.37, for a total value of $49,370.00. Following the completion of the sale, the director now directly owns 20,465 shares in the company, valued at $1,010,357.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 3,000 shares of company stock valued at $123,960 over the last 90 days. Company insiders own 19.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Assembly Biosciences (ASMB) Share Price” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/17/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-assembly-biosciences-asmb-share-price.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.